Miriam Haak

Miriam is leading the client services team, who develops custom stable producer cell lines for large scale adeno-associated virus (AAV) manufacturing. With Rep, Helper, Cap and the gene of interest incorporated into the genome, these cell lines allow enhanced scalability and reproducibility. The site focuses on cell line development to improve both AAV production robustness but also quality by reducing encapsidated host cell DNA using cell line engineering.

Miriam joined Cytiva in 2024. Prior to that, she was heading the Cell and Gene Therapy site at ProtaGene CGT GmbH, who offers vector integration site analysis services for preclinical and clinical evaluations. Before that time, she worked at Miltenyi Biotec B.V. & Co. KG in the evaluation and establishment of partnership programs in the context of Miltenyi Biotec’s BioIndistry CDMO services. She worked as an immunologist at the Max-Planck-Institute for Immunology in Freiburg, did her PhD in molecular oncology at the University of Muenster and worked at the PT-DLR in managing and developing funding priorities for the Federal Ministry of Education and Research.